InnoCare Pharma Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Beijing, Beijing and currently employs 1,146 full-time employees. The company went IPO on 2020-03-23. InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The firm focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The firm's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The firm is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The firm mainly conducts its businesses in domestic and overseas markets.
Follow-Up Questions
Who is the CEO of InnoCare Pharma Ltd?
Dr. Jisong Cui is the Executive Chairman of the Board of InnoCare Pharma Ltd, joining the firm since 2015.
What is the price performance of INCPF stock?
The current price of INCPF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for InnoCare Pharma Ltd?
InnoCare Pharma Ltd belongs to Biotechnology industry and the sector is Health Care
What is InnoCare Pharma Ltd market cap?
InnoCare Pharma Ltd's current market cap is $0
Is InnoCare Pharma Ltd a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for InnoCare Pharma Ltd, including 2 strong buy, 5 buy, 2 hold, 0 sell, and 2 strong sell
